Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Magnolia kobus bark
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Magnolia kobus bark is derived from the Magnolia kobus tree, native to Japan and Korea. It has a long history of use in traditional Chinese and Japanese medicine. Bioactive constituents found in Magnolia bark, such as honokiol and magnolol, have demonstrated antidiabetic properties. These include improving hyperglycemia, ameliorating diabetic complications, and positively influencing lipid metabolism and oxidative stress. The bark also exhibits anti-inflammatory and antioxidant effects.
- Other names
- Kobus magnolia barkKobushi magnolia barkMokryeon bark
02
Targets
ALOX5 (Arachidonate 5-lipoxygenase)CNR1 (Cannabinoid receptor 1)SLC2A4 (Solute carrier family 2 facilitated glucose transporter member 4)INSR (Insulin receptor)PTPN1 (Protein tyrosine phosphatase 1B)AMPK (Adenosine monophosphate–activated protein kinase)
Beyond the preview
Go deeper on Magnolia kobus bark.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Magnolia kobus bark.